[ad_1]

AstraZeneca backed its 2023 guidance, after it posted a first-quarter profit of $1.8 billion, beating forecasts, but said revenue from Covid-19 medicines, including its vaccine, is expected to decline significantly in 2023.

[ad_2]

Source link